Clinical Trial Update: Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

View source ↗

Summary

A Pfizer-sponsored clinical trial evaluating cefoperazone/sulbactam for serious intra-abdominal and hepatobiliary infections has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Appendicitis
• Cholecystitis
• Intra-abdominal Abscess
• Peritonitis
• Surgical Site Infection

Drugs mentioned

• Cefoperazone/Sulbactam (cefoperazone/sulbactam)

Snippet

Sponsor: Pfizer | Conditions: Abscess, Intra-Abdominal, Cholecystitis | Status: WITHDRAWN